Moving programmed death-1 inhibitors to the front lines in Non-Small-Cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 2953-2955

  Gainor, Justin F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CARBOPLATIN; CHECKPOINT KINASE INHIBITOR; DOCETAXEL; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEALTH CARE QUALITY; HUMAN; INFUSION RELATED REACTION; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR BIOPSY; LUNG TUMOR;

B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84983535198     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.1205     Document Type: Review

References (20)

1. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
2. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 372:2018-2028, 2015
3. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014
4. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
5. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
6. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
7. Fehrenbacher L, Spira A, Ballinger M, et al: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387: 1837-1846, 2016
8. National Comprehensive Cancer Network: NSCLC Guidelines v4.2016. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp
9. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
10. Thatcher N, Hirsch FR, Luft AV, et al: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763-774, 2015
11. Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255, 2012
12. Gettinger S, Rizvi NA, Chow LQ, et al: Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2980-2987, 2016
13. Rizvi NA, Hellmann MD, Brahmer JR, et al: Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2969-2979, 2016
14. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
15. Papadimitrakopoulou V, Patnaik A, Borghaei H, et al: Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C. J Clin Oncol 33, 2015 (suppl; abstr 8031)
16. Liu S, Powderly J, Camidge D, et al: Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8030)
17. Pilotto S, Carbognin L, Karachaliou N, et al: Moving towards a customized approach for drug development: Lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res 4:704-712, 2015
18. Kerr KM, Tsao MS, Nicholson AG, et al: Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 10: 985-989, 2015
19. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
20. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015